Cover Image


Autoimmune Injectables to 2020

出版商 Greystone Research Associates 商品編碼 304991
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
Back to Top
自體免疫注射劑市場 Autoimmune Injectables to 2020
出版日期: 2014年06月04日 內容資訊: 英文





  • 疾病發展和人類健康的模式
  • 疾病的發生,治療及預防的免疫疾病反應
  • 免疫疾病的連鎖
  • 受體、配體及細胞信號傳達途徑


  • FDA認證藥物
  • 患者及疾病的人口動態
  • 競爭環境
  • 規定成長的要素
  • 法規要素
  • 每服用成本和管理護理
  • 副作用、加框警語和病人依從性


  • 關節炎
  • 乾癬
  • 多發性硬化症
  • 克隆氏症
  • 紅斑性狼瘡


  • TNF
  • 成長阻礙因素
  • 白細胞介素
    • 干擾素(interferon)
  • T細胞受體抑制劑
  • 自然地免疫疾病細胞受體抑制劑
  • 激化酵素抑制劑
  • 補助刺激分子抑制劑
  • 趨化素受體
  • 轉錄因子
  • 血管黏合抑制劑
  • 類鐸受體
  • 其他免疫疾病學的因素藥物候補


  • 法規因素
    • 臨床試驗通訊協定、終點
  • 聯盟、夥伴關係


Product Code: AJR252K

In spite of the growing understanding of the underlying disease mechanisms for a host of diseases and disease families, autoimmune conditions continue to be intractable to most therapies and difficult to treat. Because of the individual genetic variability underlying the incidence and severity of autoimmune symptoms, regional variations in the market for autoimmune therapeutics can be significant. This variability is compounded by differences in treatment protocols and cultural factors, which combine to make alliance partnerships with regional players of increasing importance. Over the past two years the introduction of new and improved injectables for treating autoimmune diseases is creating new options for clinicians and patients. This optimism is being reinforced by pipeline candidates that will further the effort to improve treatment protocols for patients.


  • Analyzes current therapeutic options for autoimmune diseases, and evaluates emerging therapeutic candidates and assesses their commercial potential
  • Assesses existing and evolving immune disease mechanisms, treatment strategies and pipeline drug candidates
  • Provides data and forecasts for major autoimmune disease segments to 2020
  • Evaluates regional and global opportunities for autoimmune therapeutics

Table of Contents

Executive Summary

Immune Modulation in Disease Therapeutics

  • Evolving Models of Disease and Human Health
  • The Immune Response in Disease Incidence, Treatment & Prevention
  • The Immune Cascade
  • Receptors, Ligands and Cell Signaling Pathways

Autoimmune Disease Therapeutics- Commercial Realities

  • FDA-Approved Drugs
  • Patient and Disease Demographics
  • Competitive Landscape
  • Factors Limiting Growth
  • Regulatory Factors
  • Cost per Dose and Managed Care
  • Side Effects, Black Box Warnings and Patient Compliance

Autoimmune Disease Therapeutics - Disease Segment Analysis

  • Arthritis
  • Psoriasis
  • Multiple Sclerosis
  • Crohn's Disease
  • Lupus

Autoimmune Injectables - Indications, Market Data and Forecasts

  • TNF
  • Growth Factor inhibitors
  • Interleukins
    • Interferons
  • T-Cell Receptor Inhibitors
  • Innate Immune Cell Receptor Inhibitors
  • B-Cell Receptor Inhibitors
  • Kinase Inhibitors
  • Co-stimulator Inhibitors
  • Chemokine Receptors
  • Transcription Factors
  • Vascular Adhesion Inhibitors
  • Toll-like Receptors
  • Other Immune Factor Drug Candidates

Business Factors

  • Regulatory Factors
    • Clinical Trial Protocols & Endpoints
  • Alliances and Partnerships

Autoimmune Injectables- Company Profile

Back to Top